Mercado global de diagnóstico de transplante baseado em PCR, por tipo de teste (teste PCR CMV, teste PCR EBV, teste PCR BKV, teste PCR VZV, teste PCR HSV1, teste PCR HSV2, teste PCR Parvovirus B19, teste PCR P. Jirovecii, teste PCR JCV, Teste PCR Adenovírus e Teste PCR Aspergillus Spp), Tipo de Transplante (Transplante Rim, Transplante Hepático, Transplante Cardíaco, Transplante Pulmonar, Transplante Pâncreas e Outros Transplantes), Aplicação (Aplicações de Diagnóstico e Aplicações de Investigação), Utilizador Final (Hospitais e Centros de Transplantação , prestadores de serviços comerciais, laboratórios de investigação e institutos académicos) - Tendências e previsões do setor para 2031.
Análise e insights de mercado de diagnóstico de transplante baseado em PCR
Um dos principais fatores que impulsionam o crescimento do mercado é a crescente prevalência da falência de órgãos. Além disso, a crescente popularidade dos métodos de diagnóstico não invasivos em todo o mundo é outro fator-chave para o crescimento do mercado. Os avanços nas técnicas de preservação de órgãos também influenciam o mercado. No entanto, a escassez de profissionais com expertise no diagnóstico de transplantes está a restringir o crescimento do mercado.
Por outro lado, a iniciação estratégica e o lançamento de tecnologia por parte dos players do mercado funcionam como uma oportunidade de crescimento do mercado. No entanto, os desafios éticos enfrentados durante o transplante de órgãos podem criar um desafio ao crescimento do mercado.
A Data Bridge Market Research analisa que o mercado deverá atingir os 995.007,52 mil dólares até 2031, face aos 612.500,00 mil dólares em 2023, crescendo com um CAGR de 6,5% no período previsto de 2024 a 2031.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2024 a 2031 |
|
Ano base |
2023 |
|
Anos históricos |
2022 (personalizável para 2016-2021) |
|
Unidades Quantitativas |
Receita em mil dólares |
|
Segmentos cobertos |
Tipo de teste (teste PCR CMV, teste PCR EBV, teste PCR BKV, teste PCR VZV, teste PCR HSV1, teste PCR HSV2, teste PCR parvovírus B19, teste PCR P. Jirovecii, teste PCR JCV, teste PCR adenovírus e PCR de Aspergillus Spp Teste), Tipo de Transplante (Transplante de Rim, Transplante de Fígado , Transplante de Coração, Transplante de Pulmão, Transplante de Pâncreas e Outros Transplantes), Aplicação (Aplicações de Diagnóstico e Aplicações de Investigação), Utilizador Final (Hospitais e Centros de Transplantação, Prestadores de Serviços Comerciais, Laboratórios de Investigação, e institutos académicos) |
|
Países abrangidos |
EUA, Canadá, México, Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Holanda, Suíça, Resto da Europa, China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia , Filipinas , Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Eurofins Viracor, LLC, Sonic Healthcare USA, Ambar Lab, ARUP Laboratories e Dr. |
Definição de mercado
PCR is a molecular biology technique used to amplify specific DNA sequences, enabling the detection and analysis of genetic material with high precision and sensitivity. In the context of transplant diagnostics, PCR-based assays are employed to assess compatibility between organ donors and recipients, monitor post-transplant outcomes, and detect signs of rejection or complications. The market can be defined as the segment of the healthcare industry that focuses on utilizing PCR technology for diagnostic purposes in organ transplantation procedures.
Global PCR Based Transplant Diagnostics Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Organ Failure
There is a growing demand for organ transplants to save lives and improve the quality of life for affected individuals, as the incidence of organ failure continues to rise. Organs such as kidney, liver, heart, and lungs may fail due to various reasons, including chronic diseases, genetic disorders, or trauma. The growing prevalence of chronic diseases, such as chronic kidney disease, liver disease, and heart disease, contributes to an expanding patient pool in need of organ transplants. These patients often require transplant diagnostics to ensure compatibility between the donor organ and the recipient, minimizing the risk of rejection. Hence, the increasing prevalence of organ failure is driving the market growth.
- Rising Popularity of Non-Invasive Diagnostic Methods
Non-invasive diagnostic methods, such as blood tests and imaging techniques, eliminate the need for invasive procedures such as tissue biopsies. This results in increased patient comfort, leading to higher acceptance and compliance with diagnostic assessments. In the context of transplant diagnostics, non-invasive methods offer a less intrusive way to assess compatibility between donors and recipients. Invasive diagnostic procedures, such as tissue biopsies, carry inherent risks of complications, including bleeding and infection. Non-invasive methods, being less risky, appeal to both patients and healthcare providers. The reduction in the risk of complications is particularly significant in the context of transplant patients who may already be immuno-compromised. Hence, the rising popularity of non-invasive diagnostic methods is driving the market growth.
Opportunity
- Strategic Initiation and Technology Launches by Market Players
The escalating growth in the PCR based transplant diagnostics market, driven by the increased demand for donor organs, emphasizes the strategic initiatives such as partnerships, business expansions, and developmental endeavors. These initiatives, guided by well-thought-out strategies, include the introduction of transplant diagnostic kits, such as the Aspergillus Spp PCR Test, PCR Test, CMV PCR Test, EBV PCR Test, BKV PCR Test, and VZV PCR Test. Implementing these strategic frameworks enables market participants to harmonize with their organizational activities, enhancing operational efficiency and aligning efforts with the dynamic landscape of transplant diagnostics.
Hence, these strategic initiatives by the market players may be expected to act as an opportunity for market growth.
Restraints/Challenges
- Shortage of Professionals with Expertise in Transplant Diagnostics
Shortage of skilled professionals may result in limited accessibility to specialized transplant diagnostic services. This could be particularly challenging for healthcare facilities in regions with a scarcity of trained personnel, leading to delayed or inadequate diagnostic support for organ transplant procedures. The shortage of experts in transplant diagnostics may compromise the quality and accuracy of diagnostic assessments. Lack of specialized knowledge and experience could result in errors in interpreting test results, potentially impacting the success rates of organ transplantation.
This may also impact research and development efforts in transplant diagnostics. Insufficient expertise may slow down the pace of innovation, hindering the development of new diagnostic technologies and approaches, which is restraining the market growth
- Ethical Challenges Faced During Organ Transplantation
The escalating incidence of vital organ failures, coupled with an insufficient supply, has created a pronounced gap between the growing demand for organs and their limited availability. This critical issue has not only prolonged approval times for organ recipients but has also contributed to a rise in fatalities. In addressing this pressing challenge, PCR-based diagnostic tests play a pivotal role, helping ensure the compatibility and viability of organs for transplantation. Tests such as the HLA Typing PCR Test and Cytomegalovirus (CMV) PCR Test are instrumental in determining the compatibility between donors and recipients, aiding in efficient organ allocation and reducing approval times.
It is therefore apparent that ethical challenges faced during organ transplantation are expected to challenge market growth.
Recent Developments
- In January 2024, Laboratory Corporation of America Holdings launched a new test for preeclampsia in pregnant women which represents a significant advancement in maternal healthcare. This advanced diagnostic tools, healthcare providers can identify women at higher risk of severe preeclampsia earlier in their pregnancies. This allows the company for more vigilant monitoring and proactive medical intervention, potentially reducing the risk of complications and improving maternal and fetal outcomes
- In September 2023, Sonic Healthcare's acquired Healius Ltd., to provide development in the Australian healthcare landscape. This acquisition further solidifies Sonic's position as a global leader in pathology, strengthening its competitive edge against other international players. It signifies the company's commitment to expansion and consolidation within the industry, potentially paving the way for similar mergers in other regions
- In October 2023, Sonic Healthcare's invested in PaigeAI, an AI-powered pathology company, underscores their commitment to harnessing cutting-edge technology for improved diagnostic accuracy and efficiency in the field of pathology. This move holds significant implications for the future of medical diagnostics. This precision approach can lead to more effective treatments and potentially reduce the risk of side effects from unnecessary medications
- In August 2020, Eurofins Viracor collaborated with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America, through high-impact research and its clinical training programs. This research collaboration has further verified the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”) and its blood gene expression test, TruGraf. TruGraf can rule out “silent” subclinical kidney rejection in kidney transplant patients with stable kidney function. TGI has recently received a draft Local Coverage Determination (LCD) decision from the Centers for Medicare & Medicaid Services (CMS) via Palmetto GBA’s Molecular Diagnostic Services (MolDX) Program. This has helped the company to validate its research
- In June 2020, Transplant Genomics, Inc. and Eurofins Viracor announced the development of the Eurofins Transplant Medical and Scientific Advisory Board, engaging diverse expertise and understanding in transplantation and technology development to improve the clinical value of diagnostics throughout the transplant community. Board associates are focusing on improvement and product development, utilizing their unique perspectives to help TGI and Viracor expand to serve the unmet needs in transplantation and guide future products. This has helped the company to expand its product portfolio
Global PCR Based Transplant Diagnostics Market Scope
The global PCR based transplant diagnostics market is categorized into four notable segments based on test type, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Test Type
- CMV PCR Test
- EBV PCR Test
- BKV PCR Test
- VZV PCR Test
- HSV1 PCR Test
- HSV2 PCR Test
- Parvovirus B19 PCR Test
- P. Jirovecii PCR Test
- JCV PCR Test
- Adenovirus PCR Test
- Aspergillus Spp PCR Test
On the basis of test type, the global PCR based transplant diagnostics market is segmented into CMV PCR test, EBV PCR test, BKV PCR test, VZV PCR test, HSV1 PCR test, HSV2 PCR test, Parvovirus B19 PCR test, P. Jirovecii PCR test, JCV PCR test, Adenovirus PCR test, and Aspergillus Spp PCR test.
Transplant Type
- Kidney Transplantation
- Liver Transplantation
- Heart Transplantation
- Lung Transplantation
- Pancreas Transplantation
- Other Transplantations
On the basis of transplant type, the global PCR based transplant diagnostics market is segmented into kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other transplantations.
Application
- Diagnostic Applications
- Research Applications
On the basis of application, the global PCR based transplant diagnostics market is segmented into diagnostic application, and research applications.
End User
- Hospitals and Transplant Centers
- Commercial Service Providers
- Research Laboratories and Academic Institutes
On the basis of end user, the global PCR based transplant diagnostics market is segmented into hospitals and transplant centers, commercial service providers, and research laboratories and academic institutes.
Global PCR Based Transplant Diagnostics Market Regional Analysis/Insights
The global PCR based transplant diagnostics market is categorized into four notable segments based on test type, transplant type, application, and end user.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of major market players and increased technological advancement in the region. The U.S. is expected to dominate the North America region due to rising demand for organ transplantation in the country. Germany is expected to dominate Europe region owing to the rising awareness about the application of PCR (Polymerase Chain Reaction) based transplant diagnostics in the country. China is expected to dominate Asia-Pacific region due to rising prevalence of kidney failure across the country.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .
Análise global da quota de mercado de diagnóstico de transplante baseado em PCR e cenário competitivo
O panorama competitivo do mercado global de diagnóstico de transplante baseado em PCR fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e fôlego do produto, domínio de aplicação, tipo de produto linha de vida curva. Os dados acima fornecidos estão apenas relacionados com o foco da empresa no mercado global de diagnóstico de transplante baseado em PCR.
Alguns dos principais players que operam no mercado são a Quest Diagnostics Incorporated, a Laboratory Corporation of America Holdings, a Eurofins Viracor, LLC, a Sonic Healthcare USA, a Ambar Lab, a ARUP Laboratories e a Dr.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF ORGAN FAILURE
5.1.2 RISING POPULARITY OF NON-INVASIVE DIAGNOSTIC METHODS
5.1.3 ADVANCEMENT IN ORGAN PRESERVATIVE TECHNIQUES
5.1.4 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
5.2 RESTRAINTS
5.2.1 SHORTAGE OF PROFESSIONALS WITH EXPERTISE IN TRANSPLANT DIAGNOSTICS
5.2.2 HIGH COST OF PCR/NGS SOFTWARE
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATION AND TECHNOLOGY LAUNCHES BY MARKET PLAYERS
5.3.2 RISE IN GOVERNMENT SUPPORT AND FUNDING FOR PCR-BASED ORGAN TRANSPLANTATION
5.3.3 SURGE OF AWARENESS FOR ORGAN TRANSPLANTATION
5.4 CHALLENGES
5.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION
5.4.2 LACK OF ORGAN DONORS AND PROVIDERS ANNUALLY
6 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 CMV PCR TEST
6.3 EBV PCR TEST
6.4 BKV PCR TEST
6.5 VZV PCR TEST
6.6 HSV1 PCR TEST
6.7 HSV2 PCR TEST
6.8 PARVOVIRUS B19 PCR TEST
6.9 P. JIROVECII PCR TEST
6.1 JCV PCR TEST
6.11 ADENOVIRUS PCR TEST
6.12 ASPERGILLUS SPP PCR TEST
7 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE
7.1 OVERVIEW
7.2 KIDNEY TRANSPLANTATION
7.3 LIVER TRANSPLANTATION
7.4 HEART TRANSPLANTATION
7.5 LUNG TRANSPLANTATION
7.6 PANCREAS TRANSPLANTATION
7.7 OTHER TRANSPLANTATIONS
8 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTIC APPLICATIONS
8.3 RESEARCH APPLICATIONS
9 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS AND TRANSPLANT CENTERS
9.3 COMMERCIAL SERVICE PROVIDERS
9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
10 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 FRANCE
10.3.2 U.K.
10.3.3 SPAIN
10.3.4 GERMANY
10.3.5 TURKEY
10.3.6 ITALY
10.3.7 RUSSIA
10.3.8 NETHERLANDS
10.3.9 BELGIUM
10.3.10 SWITZERLAND
10.3.11 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 SOUTH KOREA
10.4.4 AUSTRALIA
10.4.5 JAPAN
10.4.6 THAILAND
10.4.7 PHILIPPINES
10.4.8 INDONESIA
10.4.9 MALAYSIA
10.4.10 SINGAPORE
10.4.11 REST OF ASIA-PACIFIC
10.5 SOUTH AMERICA
10.5.1 BRAZIL
10.5.2 ARGENTINA
10.5.3 REST OF SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
10.6.1 SAUDI ARABIA
10.6.2 ISRAEL
10.6.3 EGYPT
10.6.4 SOUTH AFRICA
10.6.5 U.A.E.
10.6.6 REST OF MIDDLE EAST AND AFRICA
11 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
11.3 COMPANY SHARE ANALYSIS: EUROPE
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12 SWOT ANALYSIS
13 COMPANY PROFILES
13.1 QUEST DIAGNOSTICS INCORPORATED.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 LABORATORY CORPORATION OF AMERICA HOLDINGS.
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENT
13.3 EUROFINS VIRACOR
13.3.1 COMPANY SNAPSHOT
13.3.2 COMPANY SHARE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 SONIC HEALTHCARE LIMITED
13.4.1 COMPANY SNAPSHOT
13.4.2 PRODUCT REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 DR LAL PATHLABS.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENTS
13.6 ARUP LABORATORIES
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 AMBAR LAB.
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 3 GLOBAL CMV PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL EBV PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL BKV PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL VZV PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL HSV1 PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL HSV2 PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL PARVOVIRUS B19 PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL P. JIROVECII PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL JCV PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL ADENOVIRUS PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL ASPERGILLUS SPP PCR TEST IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL KIDNEY TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL LIVER TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL HEART TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL LUNG TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL PANCREAS TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL OTHER TRANSPLANTATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL DIAGNOSTIC APPLICATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL RESEARCH APPLICATION IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL HOSPITALS AND TRANSPLANT CENTERS IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL COMMERCIAL SERVICE PROVIDERS IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL RESEARCH LABORATORIES AND ACADEMIC INSTITUTES IN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 32 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 35 U.S. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 U.S. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 37 U.S. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 40 CANADA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 41 CANADA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 42 CANADA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 43 CANADA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 44 CANADA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 45 MEXICO PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 46 MEXICO PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 47 MEXICO PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 MEXICO PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 49 MEXICO PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 50 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 51 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 53 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 55 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 56 FRANCE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 FRANCE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 58 FRANCE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 59 FRANCE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 60 FRANCE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 U.K. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.K. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 63 U.K. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 U.K. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 65 U.K. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 66 SPAIN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 67 SPAIN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 68 SPAIN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 SPAIN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 70 SPAIN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 71 GERMANY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 GERMANY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 73 GERMANY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 74 GERMANY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 75 GERMANY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 76 TURKEY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 TURKEY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 78 TURKEY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 TURKEY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 80 TURKEY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 ITALY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 ITALY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 83 ITALY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 ITALY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 85 ITALY PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 86 RUSSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 RUSSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 88 RUSSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 RUSSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 90 RUSSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 91 NETHERLANDS PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 NETHERLANDS PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 93 NETHERLANDS PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 NETHERLANDS PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 95 NETHERLANDS PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 96 BELGIUM PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 BELGIUM PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 98 BELGIUM PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 BELGIUM PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 100 BELGIUM PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 SWITZERLAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 102 SWITZERLAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 103 SWITZERLAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 SWITZERLAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 105 SWITZERLAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 106 REST OF EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 REST OF EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 108 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 109 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 111 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 113 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 114 CHINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 CHINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 116 CHINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 CHINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 118 CHINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 119 INDIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 INDIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 121 INDIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 INDIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 123 INDIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 124 SOUTH KOREA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 SOUTH KOREA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 126 SOUTH KOREA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 127 SOUTH KOREA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 128 SOUTH KOREA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 AUSTRALIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 AUSTRALIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 131 AUSTRALIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 AUSTRALIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 133 AUSTRALIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 134 JAPAN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 JAPAN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 136 JAPAN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 JAPAN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 138 JAPAN PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 139 THAILAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 THAILAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 141 THAILAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 THAILAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 143 THAILAND PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 144 PHILIPPINES PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 PHILIPPINES PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 146 PHILIPPINES PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 PHILIPPINES PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 148 PHILIPPINES PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 149 INDONESIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 INDONESIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 151 INDONESIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 INDONESIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 153 INDONESIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 154 MALAYSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 MALAYSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 156 MALAYSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 MALAYSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 158 MALAYSIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 159 SINGAPORE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SINGAPORE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 161 SINGAPORE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 SINGAPORE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 163 SINGAPORE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 164 REST OF ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 REST OF ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 166 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 167 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 169 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 171 SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 172 BRAZIL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 BRAZIL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 174 BRAZIL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 BRAZIL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 176 BRAZIL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 177 ARGENTINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 ARGENTINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 179 ARGENTINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 ARGENTINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 181 ARGENTINA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 182 REST OF SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 183 REST OF SOUTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 184 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 185 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 187 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 189 MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 190 SAUDI ARABIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 SAUDI ARABIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 192 SAUDI ARABIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 SAUDI ARABIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 194 SAUDI ARABIA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 195 ISRAEL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 ISRAEL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 197 ISRAEL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 ISRAEL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 199 ISRAEL PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 200 EGYPT PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 EGYPT PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 202 EGYPT PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 203 EGYPT PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 204 EGYPT PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 205 SOUTH AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 SOUTH AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 207 SOUTH AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 208 SOUTH AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 209 SOUTH AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 U.A.E. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 U.A.E. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
TABLE 212 U.A.E. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 U.A.E. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 214 U.A.E. PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 215 REST OF MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 REST OF MIDDLE EAST AND AFRICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (NUMBER OF TESTS)
Lista de Figura
FIGURE 1 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET SHARE ANALYSIS
FIGURE 5 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF ORGAN FAILURE IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET FROM 2024 TO 2034
FIGURE 12 CMV PCR TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET IN 2024 TO 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET AND ASIA-APCIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL DIAGNOSTICS TESTS MARKET SERVICE PROVIDERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET
FIGURE 16 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TEST TYPE, 2023
FIGURE 17 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TEST TYPE LIFELINE CURVE
FIGURE 20 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TRANSPLANT TYPE, 2023
FIGURE 21 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TRANSPLANT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TRANSPLANT TYPE, CAGR (2024-2031)
FIGURE 23 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2023
FIGURE 25 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: APPLICATION, CAGR (2024-2031)
FIGURE 27 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY END USER, 2023
FIGURE 29 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 31 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2023)
FIGURE 33 GLOBAL PCR BASED TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2023 (%)
FIGURE 34 NORTH AMERICA PCR BASED TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2023 (%)
FIGURE 35 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2023 (%)
FIGURE 36 ASIA-PACIFIC PCR BASED TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2023 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
